tbuckley/cabot-search huggingface dataset:
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma
Authors: Elizabeth R. Gerstner, Kyrre E. Emblem, Ken Chang, Bella Vakulenko-Lagun, Yi-Fen Yen, Andrew L. Beers, Jorg Dietrich, Scott R. Plotkin, Ciprian Catana, Jacob M. Hooker, Dan G. Duda, Bruce Rosen, Jayashree Kalpathy-Cramer, Rakesh K. Jain, Tracy Batchelor
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Targeting tumor blood vessels is an attractive therapy in glioblastoma (GBM), but the mechanism of action of these agents and how they modulate delivery of concomitant chemotherapy are not clear in humans. We sought to elucidate how bevacizumab modulates tumor vasculature and the impact those vascular changes have on drug delivery in patients with recurrent GBM. Experimental Design: Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide. PET-MRI scans were performed prior to the first bevacizumab dose, 1 day after the first dose, and prior to the third dose of bevacizumab. We calculated tumor volume, vascular permeability (Ktrans), perfusion (cerebral blood flow), and the standardized uptake values (SUV) of [11C] temozolomide within the tumor. Results: Twelve patients were enrolled, resulting in 23 evaluable scans. Within the entire contrast-enhancing tumor volume, both temozolomide uptake and vascular permeability decreased after initiation of bevacizumab in most patients, whereas change in perfusion was more variable. In subregions of the tumor where permeability was low and the blood–brain barrier not compromised, increased perfusion correlated with increased temozolomide uptake. Conclusions: Bevacizumab led to a decrease in permeability and concomitant delivery of temozolomide. However, in subregions of the tumor where permeability was low, increased perfusion improved delivery of temozolomide, suggesting that perfusion may modulate the delivery of chemotherapy in certain settings. These results support exploring whether lower doses of bevacizumab improve perfusion and concomitant drug delivery.
Widespread temporal coding of cognitive control in the human prefrontal cortex
Authors: Elliot H. Smith, Guillermo Horga, Mark J. Yates, Charles B. Mikell, Garrett P. Banks, Yagna J. Pathak, Catherine A. Schevon, Guy M. McKhann, Benjamin Y. Hayden, Matthew M. Botvinick, Sameer A. Sheth
Journal: Nature Neuroscience (2019)
TCT-623 Objective Identification of Stenoses Inducing Myocardial Ischemia Using Sequential iFR, FFR and Intracoronary Flow Measurements
Authors: Valérie Stegehuis, Gilbert Wijntjens, Sukhjinder Nijjer, Guus de Waard, Tim van de Hoef, Ricardo Petraco, Mauro Echavarria Pinto, Hernan Mejia-Renteria, Martijn Meuwissen, Ibrahim Danad, Paul Knaapen, Javier Escaned, Justin Davies, Niels van Royen, Jan Piek
Journal: Journal of the American College of Cardiology (2019)
TCT-499 App Based Remote Monitoring and Virtual Review Following ST-Segment Elevation Myocardial Infarction (STEMI)
Authors: George Thornton, Debashish Das, Lizzie Moore, Oliver Casey-Gillman, Susannah Adey, Ajay Jain, Oliver Guttmann, Anthony Mathur, Daniel Jones
Journal: Journal of the American College of Cardiology (2019)
Proximity to major roadways and asthma symptoms in the School Inner-City Asthma Study
Authors: Marissa Hauptman, Jonathan M. Gaffin, Carter R. Petty, William J. Sheehan, Peggy S. Lai, Brent Coull, Diane R. Gold, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2019)
TCT-763 Valve in Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement: Real World Outcomes From the National Inpatient Sample (2013–2016)
Authors: Grant Kim, Arnar Geirsson, Michael Cleman, John Forrest, Ryan Kaple
Journal: Journal of the American College of Cardiology (2019)
TCT-308 Impact of Periprocedural Major Adverse Events After PCI and CABG on Long-Term Outcomes in Patients With Left Main Disease: The EXCEL Trial
Authors: Sneha Jain, Ovidiu Dressler, Patrick Serruys, A. Pieter Kappetein, Joseph Sabik, Martin Leon, David Taggart, Marie-Claude Morice, John Puskas, David Kandzari, Nicholas Lembo, William Brown, Adrian Banning, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study
Authors: Yahia Al-Jebari, Angel Elenkov, Elin Wirestrand, Indra Schütz, Aleksander Giwercman, Yvonne Lundberg Giwercman
Journal: BMJ (2019)

Abstract Objective To compare the risk and severity of prostate cancer between men achieving fatherhood by assisted reproduction and men conceiving naturally. Design National register based cohort study. Setting Sweden from January 1994 to December 2014. Participants 1 181 490 children born alive in Sweden during 1994-2014 to the same number of fathers. Fathers were grouped according to fertility status by mode of conception: 20 618 by in vitro fertilisation (IVF), 14 882 by intra-cytoplasmic sperm injection (ICSI), and 1 145 990 by natural conception. Main outcome measures Prostate cancer diagnosis, age of onset, and androgen deprivation therapy (serving as proxy for advanced or metastatic malignancy). Results Among men achieving fatherhood by IVF, by ICSI, and by non-assisted means, 77 (0.37%), 63 (0.42%), and 3244 (0.28%), respectively, were diagnosed as having prostate cancer. Mean age at onset was 55.9, 55.1, and 57.1 years, respectively. Men who became fathers through assisted reproduction had a statistically significantly increased risk of prostate cancer compared with men who conceived naturally (hazard ratio 1.64, 95% confidence interval 1.25 to 2.15, for ICSI; 1.33, 1.06 to 1.66, for IVF). They also had an increased risk of early onset disease (that is, diagnosis before age 55 years) (hazard ratio 1.86, 1.25 to 2.77, for ICSI; 1.51, 1.09 to 2.08, for IVF). Fathers who conceived through ICSI and developed prostate cancer received androgen deprivation therapy to at least the same extent as the reference group (odds ratio 1.91; P=0.07). Conclusions Men who achieved fatherhood through assisted reproduction techniques, particularly through ICSI, are at increased risk for early onset prostate cancer and thus constitute a risk group in which testing and careful long term follow-up for prostate cancer may be beneficial.
Response by Scally and Dawson to Letters Regarding Article, “Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy”
Authors: Caroline Scally, Dana K. Dawson
Journal: Circulation (2019)

difference between the 2 groups at follow-up.There were no significant differences in monocyte subpopulation analysis or inflammatory cytokines between emotional versus physical stressor groups at any time.Last, although we agree that immune checkpoint inhibitors can trigger immune cascades resulting in either severe myocarditis or a takotsubo-like presentation, we did not include any patients with past or current malignancy in the study cohort, as they would have been a clear confounder to our prespecified end points.
Quantitative Results of a National Intervention to Prevent<i>Clostridioides difficile</i>Infection
Authors: Erik R. Dubberke, Jeffrey M. Rohde, Sanjay Saint, Karen Jones, Ashley Snyder, Andrew J. Rolle, Vineet Chopra
Journal: Annals of Internal Medicine (2019)

Background: Clostridioides difficile infection (CDI) is on the rise. Objective: To evaluate the effect of a tiered, evidence-based intervention to prevent CDI. Design: Pre–post observational evaluation of a prospective, 12-month, national, nonrandomized, clustered quality improvement project to reduce hospital health care–associated infection. Setting: Acute care, long-term acute care, and critical access hospitals working with state partner organizations (state hospital associations and state health departments) to improve health care–associated infection prevention practices. Participants: Targeted hospitals had a high burden of CDI and another health care–associated infection. Other hospitals that did not meet these criteria volunteered to participate. Intervention: Multimodal intervention that consisted of 1) on-demand educational modules and webinars, 2) in-person meetings facilitated by state-level partners, 3) feedback and recommendations for implementation of evidence-based recommendations (including a CDI-specific guide on which interventions to implement), and 4) guided facilitation through infection prevention resources and site visits. Measurements: Pre- and postintervention CDI rates. Results: Between November 2016 and May 2018, 387 hospitals (366 of which reported CDI data) in 23 states and the District of Columbia participated in the intervention. There was a statistically significant decrease in CDI incidence over the study period, from 7.0 cases per 10 000 patient-days in the preintervention period to 5.7 cases per 10 000 patient-days in the postintervention period. However, this decrease appeared to be part of a temporal trend rather than due to the study intervention. Limitations: Commitment to and adherence with recommended infection prevention practices before and after the intervention were not assessed. The intervention period was relatively brief, and patient-level data were not available. Conclusion: Although a statistically significant decline in hospital-onset CDI was observed, this trend appears to be unrelated to the study intervention. Primary Funding Source: Centers for Disease Control and Prevention.
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Emily Y. Jen, Xin Gao, Liang Li, Luning Zhuang, Natalie E. Simpson, Baikuntha Aryal, Rong Wang, Donna Przepiorka, Yuan Li Shen, Ruby Leong, Chao Liu, Christopher M. Sheth, Steven Bowen, Kirsten B. Goldberg, Ann T. Farrell, Gideon M. Blumenthal, Richard Pazdur
Journal: Clinical Cancer Research (2019)

Abstract Tagraxofusp-erzs (Elzonris, Stemline) is a cytotoxin that targets CD123-expressing cells. On December 21, 2018, FDA approved tagraxofusp-erzs for the treatment of blastic plasmacytoid dendritic cell neoplasms (BPDCN) in adult and pediatric patients 2 years and older. Approval was based on the response rate in a single-arm trial, Study STML-401-0114; the pivotal cohort included 13 patients with treatment-naïve BPDCN who received tagraxofusp-erzs monotherapy. The complete response or clinical complete response (CR/CRc) rate in the pivotal cohort was 54% (95% CI: 25%–81%), and the median duration of CR/CRc was not reached with a median follow-up of 11.5 months (range: 0.2–12.7). In a separate exploratory cohort, a CR/CRc was achieved by 2 (13%) patients with R/R BPDCN. Safety was assessed in 94 patients with myeloid neoplasms treated with tagraxofusp-erzs at the approved dose and schedule. The major toxicity was capillary leak syndrome (CLS), which occurred in 55% of patients and was fatal in 2%. Hepatotoxicity and hypersensitivity reactions were reported in 88% and 46% of patients, respectively. Other common (≥30%) adverse reactions were nausea, fatigue, peripheral edema, pyrexia, and weight increase. A high proportion of patients (85%) developed neutralizing antidrug antibodies. Tagraxofusp-erzs is the first FDA-approved treatment for BPDCN.
Shedding of OXA-181 carbapenemase-producing Escherichia coli from companion animals after hospitalisation in Switzerland: an outbreak in 2018
Authors: Aurélien Nigg, Michael Brilhante, Valentina Dazio, Mathieu Clément, Alexandra Collaud, Stefanie Gobeli Brawand, Barbara Willi, Andrea Endimiani, Simone Schuller, Vincent Perreten
Journal: Eurosurveillance (2019)

Background Carbapenem-resistant Enterobacteriaceae pose a serious threat to public health worldwide, and the role of companion animals as a reservoir is still unclear. Aims This 4-month prospective observational study evaluated carriage of carbapenem-resistant Enterobacteriaceae at admission and after hospitalisation in a large referral hospital for companion animals in Switzerland. Methods Rectal swabs of dogs and cats expected to be hospitalised for at least 48 h were taken from May to August 2018 and analysed for the presence of carbapenem-resistant Enterobacteriaceae using selective agar plates. Resistant isolates were further characterised analysing whole genome sequences for resistance gene and plasmid identification, and ad hoc core genome multilocus sequence typing. Results This study revealed nosocomial acquisition of Escherichia coli harbouring the carbapenemase gene bla OXA-181 , the pAmpC cephalosporinase gene bla CMY-42 as well as quinolone resistance associated with qnrS1 and mutations in the topoisomerases II (GyrA) and IV (ParC). The bla OXA-181 and qnrS1 genes were identified on a 51 kb IncX3 plasmid and bla CMY-42 on a 47 kb IncI1 plasmid. All isolates belonged to sequence type ST410 and were genetically highly related. This E. coli clone was detected in 17 of 100 dogs and four of 34 cats after hospitalisation (21.6%), only one of the tested animals having tested positive at admission (0.75%). Two positive animals were still carriers 4 months after hospital discharge, but were negative after 6 months. Conclusions Companion animals may acquire carbapenemase-producing E. coli during hospitalisation, posing the risk of further dissemination to the animal and human population and to the environment.
TCT-10 Time and Mortality in ST-Segment Elevation Myocardial Infarction: Insights From the TOTAL Trial
Authors: Rachel Moxham, Vladimir Dzavik, John Cairns, Madhu Natarajan, Kevin Bainey, Elie Akl, Michael Tsang, Shahar Lavi, Warren Cantor, Sasko Kedev, Goran Stankovic, Yan Yun Liu, Sanjit Jolly
Journal: Journal of the American College of Cardiology (2019)
TCT-704 Long-Term Bleeding Following Transcatheter Aortic Valve Replacement in Patients With Chronic Kidney Disease Is Associated With Increased Mortality
Authors: Shawn Li, Nilay Patel, Laura Flannery, Ricardo Cigarroa, Ayman Shaqdan, Phoebe Erickson, Arpi Tavil-Shatelyan, Sammy Elmariah
Journal: Journal of the American College of Cardiology (2019)
TCT-816 The Optimal Timing of Mechanical Circulatory Support in Acute Myocardial Infarction Patients With Refractory Cardiogenic Shock
Authors: Ki Hong Choi, Jeong Hoon Yang, Daivd Hong, Taeho Youn, Sang Yoon Lee, Taek Kyu Park, Joo Myung Lee, Young Bin Song, Joo-Yong Hahn, Kyu Tae Park, Seung-Hyuk Choi, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2019)
TCT-34 Bioprosthetic Valve Fracture Can Eliminate Pre-Existing Prothesis-Patient Mismatch
Authors: Christina Brinkmann, Janarthanan Sathananthan, John Webb, James Cockburn, David Hildick-Smith, Oliver Bhadra, Lenard Conradi, Mizuki Miura, Maurizio Taramasso, Thomas Pilgrim, Stephan Windecker, Francesco Bedogni, Luca Testa, Joris Ooms, Nicolas Van Mieghem, Darren Mylotte, Mohamed Abdel-Wahab, David Holzhey, Alexander Wolf, Laila Cheddadi, Didier Tchetche, Joachim Schofer
Journal: Journal of the American College of Cardiology (2019)
TCT-829 Intensity of Lipid Lowering Therapy Among Patients With Prior or New Revascularization: Insights From the GOULD Registry
Authors: Benjamin Peterson, Deepak Bhatt, Christie Ballantyne, James de Lemos, Katherine Mues, Shushama Alam, Mikhail Kosiborod, Christopher Cannon
Journal: Journal of the American College of Cardiology (2019)
Abstract #2627: Studies on glyphosate induced tumorigenesis in mouse skin: A proteomic approach
Authors: Jasmine Goerge, Sahdeo Prasad, Yogeshwer Shukla
Journal: Cancer Research (2009)

Glyphosate, an organophosphate herbicide has been extensively used by agricultural workers for controlling the weeds. Glyphosate formulations are reported to cause adverse health effects in various in-vitro and in-vivo studies. So far there is no report about the tumorigenic risk associated with glyphosate exposure. However, it has been reported to induce DNA damage in rodents. In the present study, tumorigenic potential of glyphosate (25 mg/kg b.wt, topically, 3 times/week) has been evaluated in Swiss albino mouse in 2-stage initiation-promotion protocol of carcinogenesis. The results revealed that glyphosate has tumor promoting potential, in mouse skin model. However glyphosate treatment failed to provoke tumorigenesis when tested for tumor initiating and complete carcinogenic activity. Further a proteomic approach, based upon 2-dimensional gel electrophoresis (2-DE) coupled to matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF/TOF) and liquid chromatography mass spectrometry (LC-MS) was used for the comparison of differentially expressed proteins which were modulated both by the topical exposure of glyphosate and certain other known tumor promoters e.g. 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and Croton oil. The result showed that total 23 spots were differentially expressed (>2 fold) among the treated groups as compared with untreated group. Among them, proteins (translation elongation factor eEF-1 alpha chain, carbonic anhydrase III, annexin II, calcyclin, fab fragment anti-VEGF antibody, peroxiredoxin -2, superoxide dismutase [Cu-Zn], stefin A3, calgranulin -B) were common between glyphosate and TPA treated skin tissues. These proteins were mainly involved in apoptosis and growth-inhibition, anti-oxidation, energy metabolism, angiogenesis, calcium binding and protein biosynthesis processes. From the proteomics results it is concluded that glyphosate application on skin of swiss albino mice generates similar response in terms of differential protein expression as shown by TPA, a well known strong promoter of carcinogenesis. Taken together, the combinations of 2-stage mouse skin carcinogenesis model and proteomic analysis suggest that glyphosate has tumor promoting potential in skin carcinogenesis.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2627.
A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study
Authors: Tineke Cantaert, Laurence Borand, Lauriane Kergoat, Chanthy Leng, Sivlin Ung, Sotheary In, Yiksing Peng, Chandara Phoeun, Chanthy Hing, Chun Navy Taing, Manil Saman, Sivuth Ong, Channa Mey, Rithy Choeung, Sowath Ly, Philippe Dussart, Hervé Bourhy, Arnaud Tarantola
Journal: The Lancet Infectious Diseases (2019)
TCT-805 Impact of Major Vascular Complications on Outcome Following Transfemoral Transcatheter Aortic Valve Replacement
Authors: Noriaki Moriyama, Teemu Laakso, Peter Raivio, Sebastian Dahlbacka, Eeva-Maija Kinnunen, Tatu Juvonen, Antti Valtola, Matti Niemela, Markku Eskola, Fausto Biancari, Mika Laine
Journal: Journal of the American College of Cardiology (2019)
TCT-453 Does Obesity Impact In-Hospital Outcomes After Transcatheter Mitral Valve Replacement? Insights From the National Inpatient Sample
Authors: Kranthi Sitammagari, Venkata Dontaraju, Bharat Reddy Dhanireddy, Rupak Desai, Divya Kondamareddy, Jacob Ninan, Pedro Villablanca
Journal: Journal of the American College of Cardiology (2019)
Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study
Authors: Jason Fangusaro, Shengjie Wu, Shannon MacDonald, Erin Murphy, Dennis Shaw, Ute Bartels, Soumen Khatua, Mark Souweidane, Hsiao-Ming Lu, David Morris, Ashok Panigrahy, Arzu Onar-Thomas, Maryam Fouladi, Amar Gajjar, Girish Dhall
Journal: Journal of Clinical Oncology (2019)

Stratum 1 of ACNS1123 (ClinicalTrials.gov identifier: NCT01602666), a Children's Oncology Group phase II trial, evaluated efficacy of reduced-dose and volume of radiotherapy (RT) in children and adolescents with localized nongerminomatous germ cell tumors (NGGCTs). The primary objective was to evaluate the impact of reduced RT on progression-free survival (PFS) with a goal of preserving neurocognitive function.Patients received six cycles of chemotherapy with carboplatin and etoposide alternating with ifosfamide and etoposide, as used in the Children's Oncology Group predecessor study (ACNS0122; ClinicalTrials.gov identifier: NCT00047320). Patients who achieved a complete response (CR) or partial response (PR) with or without second-look surgery were eligible for reduced RT, defined as 30.6 Gy whole ventricular field and 54 Gy tumor-bed boost, compared with 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost used in ACNS0122.A total of 107 eligible patients were enrolled. Median age was 10.98 years (range, 3.68 to 21.63) and 75% were male. Sixty-six of 107 (61.7%) achieved a CR or PR and proceeded to reduced RT. The 3-year PFS and overall survival and standard error values were 87.8% ± 4.04% and 92.4% ± 3.3% compared with 92% and 94.1%, respectively, in ACNS0122. There were 10 recurrences, prompting early study closure; however, after a retrospective central review, only disease in eight of 66 (12.1%) patients eligible for reduced RT subsequently progressed; six patients had distant spinal relapse alone and two had disease with combined local plus distant relapse. Serum and CSF α-fetoprotein and β-human chorionic gonadotropin levels were not associated with PFS.Patients with localized NGGCT who achieved a CR or PR to chemotherapy and received reduced RT had encouraging PFS similar to patients in ACNS0122 who received full-dose craniospinal irradiation. However, the patterns of failure were distinct, with all patients having treatment failure in the spine.
TCT-128 Impact of Gender on Clinical Outcomes of Septal Myectomy Versus Alcohol Septal Ablation for Hypertrophic Cardiomyopathy in the United States
Authors: Tarun Jain, Alejandro Lemor, Pedro Villablanca, Dee Dee Wang, Mayra Guerrero, Igor Palacios, Tiberio Frisoli, Marvin Eng, William O'Neill
Journal: Journal of the American College of Cardiology (2019)
Abstract 15928: Hospitalization Rates and Costs Among Real World Users of Sacubitril/Valsartan versus Other Heart Failure Medications
Authors: Lauren Parlett, Aliza Gordon, Malgorzata Sylvestrzak, Jeff White, Thomas Power, John Barron
Journal: Circulation (2018)

Introduction: Sacubitril/valsartan (SV) is a heart failure (HF) drug approved in 2015 that showed benefit compared to enalapril in patients with systolic heart failure (SHF) in clinical trials, but...